BAYER AG- ADR operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BAYER AG- ADR with three other
companies in this sector in the United States:
sales of $49.44 billion
of which 66%
was innovative medicines),
of which 55%
was Operating Segment-Global Innovative Phar), and
Roche Holding Aktiengesellschaft
of which 77%
BAYER AG- ADR reported sales of $51.62 billion
December of 2016.
a very small
increase of 1.0%
versus 2015, when the company's sales were $51.09 billion.
Despite this increase, sales are still
below the level achieved in 2014, when BAYER AG- ADR
reported sales of $55.77 billion.
The sales level in 2016 was fairly close to the level five years ago: in 2011, BAYER AG- ADR had sales
of $51.05 billion.
Sales of Reconciliations saw an increase
that was more than double the company's growth rate: sales were up
50.1% in 2016, from
$4.41 million to $6.62 million.
BAYER AG- ADR also saw significant increases in sales in
Pharmaceuticals and Biological Products (up 19.5% to $18.12 billion)
Not all segments of BAYER AG- ADR experienced an increase in sales in 2016:
sales of Consumer Care fell 33.8% to $6.66 billion.
BAYER AG- ADR also experienced decreases in sales in
Cropscience (down 4.3% to $10.94 billion)
All Other Segments (down 4.9% to $1.15 billion)